ID Source | ID |
---|---|
PubMed CID | 44468216 |
CHEMBL ID | 2016757 |
CHEBI ID | 147281 |
SCHEMBL ID | 10120689 |
Synonym |
---|
c12h13n5o4 |
gs-441524 , |
evo 984 |
(2r,3r,4s,5r)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carbonitrile |
gs 441524 |
evo-984 |
evo984 |
1191237-69-0 |
gs441524 |
CHEBI:147281 |
CHEMBL2016757 |
S6814 |
SCHEMBL10120689 |
AC-31365 |
D78523 |
BRDWIEOJOWJCLU-LTGWCKQJSA-N |
HY-103586 |
BS-14744 |
gs 441524 [who-dd] |
BCP29949-1 |
EX-A3056 |
(2r,3r,4s,5r)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)oxolane-2-carbonitrile |
1bqk176dt6 , |
d-altrononitrile, 2-c-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-2,5-anhydro- |
(2r,3r,4s,5r)-2-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furancarbonitrile |
unii-1bqk176dt6 |
2-c-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-2,5-anhydro-d-altrononitrile |
(2~{r},3~{r},4~{s},5~{r})-2-(4-azanylpyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-(hydroxymethyl)-3,4-bis(oxidanyl)oxolane-2-carbonitrile |
u08 , |
C22275 |
reacted form |
(2r,3r,4s,5r)-2-{4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl}-3,4-dihydroxy-5-(hydroxymethyl)oxolane-2-carbonitrile |
CS-0028160 |
A933921 |
mfcd32666994 |
remdesivir metabolite(gs-441524) |
2-c-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2,5-anhydro-d-altrononitrile |
remdesivir related compound 6 (gs-441524) |
ZB1788 |
AKOS037648588 |
gtpl11445 |
DTXSID201028047 |
(2r,3r,4s,5r)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)oxolane-2-carbonitrile |
(2r,3r,4s,5r)-2-(4-aminopyrrolo[1,2-f][1,2,4]triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carbonitrile |
remdesivir intermediate(gs-441524) |
EN300-26870141 |
bdbm50571531 |
Z3952165305 |
To study the pharmacokinetic inter-individual variability of remdesivir and its main metabolite GS-441524 in a real-world setting of COVID-19 inpatients. To identify possible associations with different demographic/biochemical variables.
Excerpt | Reference | Relevance |
---|---|---|
" In spite of United States Food and Drug Administration's recent assent of remdesivir as the only approved agent for COVID-19, there is limited information available about the physicochemical, metabolism, transport, pharmacokinetic (PK), and drug-drug interaction (DDI) properties of this drug." | ( Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions. Deb, S; Reeves, AA, 2021) | 0.62 |
" Physiologically based pharmacokinetic (PBPK) modeling of GastroPlus was used to simulate different patient populations based on age, weight, liver function, and renal function status." | ( Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions. Deb, S; Reeves, AA, 2021) | 0.62 |
"7%, respectively) in mice, which provided good insight into the pharmacokinetic optimization of GS-441524." | ( Potency and pharmacokinetics of GS-441524 derivatives against SARS-CoV-2. Aisa, HA; Hu, T; Shen, J; Wei, D; Xie, Y; Xue, H; Zhang, Y; Zheng, W, 2021) | 1.12 |
" Here, we evaluated GS-441524 for Covid-19 treatment based on studies reporting pharmacokinetic parameters of the agent in mice, rats, cats, dogs, monkeys, and the single individual in the first-in-human trial supplemented with information about its activity against severe acute respiratory syndrome coronavirus 2 and safety." | ( Nucleoside analog GS-441524: pharmacokinetics in different species, safety, and potential effectiveness against Covid-19. Hansen, PR; Rasmussen, HB; Thomsen, R, 2022) | 1.38 |
" A prospective observational pharmacokinetic study was performed in non-critically ill hospitalized COVID-19 patients with hypoxemia." | ( Population Pharmacokinetics of Remdesivir and GS-441524 in Hospitalized COVID-19 Patients. Bosma, LBE; Leegwater, E; Moes, DJAR; Ottens, TH; van der Meer, IM; van Nieuwkoop, C; Wilms, EB, 2022) | 0.98 |
"To study the pharmacokinetic inter-individual variability of remdesivir and its main metabolite GS-441524 in a real-world setting of COVID-19 inpatients and to identify possible associations with different demographic/biochemical variables." | ( Interpatient variability in the pharmacokinetics of remdesivir and its main metabolite GS-441524 in treated COVID-19 subjects. Agrati, C; Ascoli Bartoli, T; Benvenuto, D; Marchioni, L; Nicastri, E; Stazi, GV; Tempestilli, M, 2022) | 1.16 |
" Linear regression, logistic regression and multiple linear regression tests were used for statistical comparisons of pharmacokinetic parameters and variables." | ( Interpatient variability in the pharmacokinetics of remdesivir and its main metabolite GS-441524 in treated COVID-19 subjects. Agrati, C; Ascoli Bartoli, T; Benvenuto, D; Marchioni, L; Nicastri, E; Stazi, GV; Tempestilli, M, 2022) | 0.94 |
Excerpt | Reference | Relevance |
---|---|---|
" In spite of United States Food and Drug Administration's recent assent of remdesivir as the only approved agent for COVID-19, there is limited information available about the physicochemical, metabolism, transport, pharmacokinetic (PK), and drug-drug interaction (DDI) properties of this drug." | ( Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions. Deb, S; Reeves, AA, 2021) | 0.62 |
" Subsequently, these data were used in the Drug-Drug Interaction module to simulate drug interaction potential of remdesivir with other COVID-19 drug regimens and with agents used for comorbidities." | ( Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions. Deb, S; Reeves, AA, 2021) | 0.62 |
Oral-dosed ATV041 resulted in favorable bioavailability and rapid tissue distribution of GS-441524 and ibuprofen. However, the low oral bioavailability poses a challenge to its anti-SARS-CoV-2 efficacy.
African green monkeys (AGM) orally dosed with GS-441524 yielded low plasma levels due to limited oral bioavailability of <10%. An induction dosage of remdesivir 10 to 15 mg/kg intravenously or subcutaneously q24h was utilized for 4 doses.
Role | Description |
---|---|
drug metabolite | null |
antiviral agent | A substance that destroys or inhibits replication of viruses. |
anticoronaviral agent | Any antiviral agent which inhibits the activity of coronaviruses. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
pyrrolotriazine | Any organic heterobicyclic compound containing ortho-fused pyrrolidine and triazine rings. |
nitrile | A compound having the structure RC#N; thus a C-substituted derivative of hydrocyanic acid, HC#N. In systematic nomenclature, the suffix nitrile denotes the triply bound #N atom, not the carbon atom attached to it. |
C-nucleoside | |
aromatic amine | An amino compound in which the amino group is linked directly to an aromatic system. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
RNA-directed RNA polymerase | IC50 (µMol) | 5.6000 | 0.0190 | 2.5279 | 8.8000 | AID1764901 | |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1440653 | Antiviral activity against GFP-fused Ebolavirus infected in TERT-immortalized HMVEC assessed as reduction in viral replication preincubated with cells followed by viral infection measured after 3 to 4 days by fluorescence assay | 2017 | Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5 | Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. |
AID1898378 | AUC(0 to t) in Sprague-Dawley rat at 30 mg/kg, ig measured over 48 hrs by HPLC/MS analysis | 2022 | Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4 | Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models. |
AID1853874 | Antiviral activity against Nipah M1999 infected in human HeLa cells assessed as reduction in viral replication incubated for 48 to 144 hrs by reporter virus assay | 2022 | ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3 | Phosphoramidate Prodrugs Continue to Deliver, The Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2. |
AID1764946 | Drug metabolism in cynomolgus monkey assessed as 1-NTP metabolite concentration in main stem bronchi at 20 mg/kg, iv measured after 24 hrs by LC-MS/MS analysis | |||
AID1898388 | Toxicity in BALB/c mouse infected with MHV-A59 assessed as change in body weight at 100 mg/kg, ip administered at 0.5 hrs post infection followed by 50 mg/kg administered daily measured upto 14 days | 2022 | Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4 | Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models. |
AID1750788 | Antiviral activity against Human coronavirus 229E infected in human embryonic lung fibroblast cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTS cell viability assay | 2021 | Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9 | Betulonic Acid Derivatives Interfering with Human Coronavirus 229E Replication via the nsp15 Endoribonuclease. |
AID1853868 | Antiviral activity against Ebola infected in human macrophages assessed as reduction in viral replication | 2022 | ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3 | Phosphoramidate Prodrugs Continue to Deliver, The Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2. |
AID656928 | Antiviral activity against West nile virus NY99 infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathic effect after 24 hrs by MTS assay | 2012 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8 | Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. |
AID1440652 | Antiviral activity against Ebolavirus Kikwit infected in human HeLa cells assessed as reduction in viral glycoprotein levels preincubated with cells for 2 hrs followed by viral infection measured after 48 hrs by immunostaining based assay | 2017 | Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5 | Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. |
AID1853902 | Antiviral activity against MERS-CoV infected in HAE cells assessed as reduction in viral replication at MOI of 0.5 incubated for 3 hrs followed by virus removal measured after 48 hrs by Hoechst 33258 staining based assay | 2022 | ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3 | Phosphoramidate Prodrugs Continue to Deliver, The Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2. |
AID1898382 | Tmax in Sprague-Dawley rat at 30 mg/kg, ig measured over 48 hrs by HPLC/MS analysis | 2022 | Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4 | Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models. |
AID1750810 | Inhibition of nsp15 T66I drug-resistant mutant in Human coronavirus 229E infected in human embryonic lung fibroblast cells assessed as reduction in virus yield | 2021 | Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9 | Betulonic Acid Derivatives Interfering with Human Coronavirus 229E Replication via the nsp15 Endoribonuclease. |
AID1778631 | Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability incubated for 1 to 2 hrs by MTS assay | 2021 | European journal of medicinal chemistry, Oct-05, Volume: 221 | 1,2,4-Triazolo[1,5-a]pyrimidines: Efficient one-step synthesis and functionalization as influenza polymerase PA-PB1 interaction disruptors. |
AID1750791 | Selectivity index, ratio of CC50 for cytotoxicity against mock-infected human embryonic lung fibroblast cells incubated for 5 days by MTS assay to EC50 for antiviral activity against Human coronavirus 229E infected in human embryonic lung fibroblast cells | 2021 | Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9 | Betulonic Acid Derivatives Interfering with Human Coronavirus 229E Replication via the nsp15 Endoribonuclease. |
AID656931 | Antiviral activity against SARS coronavirus Toronto-2 infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathic effect after 24 hrs by MTS assay | 2012 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8 | Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. |
AID1898373 | Antiviral activity against SARS-COV 2 infected in human Caco-2 cells assessed as inhibition of viral replication after 48 hrs by qRT-PCR analysis | 2022 | Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4 | Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models. |
AID1898395 | Half life in human plasma at 3 to 225 mg, iv administered as 2 hr infusion | 2022 | Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4 | Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models. |
AID1764900 | Inhibition of RSV RNP complex transcription incubated for 90 mins by agarose gel electrophoresis assay | |||
AID1764912 | Oral bioavailability in cynomolgus monkey at 20 mg/kg by LC-MS/MS method | |||
AID1707633 | Antitrypanosomal activity against Trypanosoma brucei brucei | 2021 | European journal of medicinal chemistry, Feb-15, Volume: 212 | Synthesis and evaluation of a collection of purine-like C-nucleosides as antikinetoplastid agents. |
AID1764901 | Inhibition of HCV NS5B RNA-dependent RNA polymerase using sshRNA template preincubated for 5 mins followed by compound addition and measured after 90 mins | |||
AID1764932 | Terminal half life in cynomolgus monkey at 20 mg/kg, iv after 30 mins by LC-MS/MS analysis | |||
AID1853882 | Antiviral activity against SARS-CoV infected in HAE cells assessed as reduction in viral replication at MOI of 0.5 preincubated for 3 hrs followed by virus removal measured after 48 hrs by Hoechst 33258 staining based assay | 2022 | ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3 | Phosphoramidate Prodrugs Continue to Deliver, The Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2. |
AID1764919 | Drug metabolism in normal human bronchial epithelial cells assessed as 1-NTP metabolite concentration at 1 uM over 48 hrs by LC-MS/MS analysis | |||
AID1440655 | Antiviral activity against Hepatitis C virus genotype 1b infected in human HuH7 cells preincubated with cells for 3 days followed by viral infection by luciferase assay | 2017 | Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5 | Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. |
AID1766168 | Antiviral activity against SARS-CoV-2 nCoV-2019BetaCoV/Wuhan/WIV04/ infected in African green monkey Vero E6 cells assessed as inhibition of viral replication when host cells were pretreated for 1 hr followed by viral infection then followed by removal of | 2021 | Bioorganic & medicinal chemistry, 09-15, Volume: 46 | Potency and pharmacokinetics of GS-441524 derivatives against SARS-CoV-2. |
AID1766166 | Antiviral activity against SARS-CoV-2 nCoV-2019BetaCoV/Wuhan/WIV04/ infected in African green monkey Vero E6 cells assessed as inhibition of viral replication at 5 uM when host cells were pretreated for 1 hr followed by viral infection then followed by re | 2021 | Bioorganic & medicinal chemistry, 09-15, Volume: 46 | Potency and pharmacokinetics of GS-441524 derivatives against SARS-CoV-2. |
AID1707638 | Cytotoxicity against mouse primary macrophages assessed as reduction in cell viability | 2021 | European journal of medicinal chemistry, Feb-15, Volume: 212 | Synthesis and evaluation of a collection of purine-like C-nucleosides as antikinetoplastid agents. |
AID1764909 | Permeability across basolateral to apical side in human Caco-2 cells | |||
AID1898379 | Terminal elimination half life in Sprague-Dawley rat at 30 mg/kg, iv measured over 48 hrs by HPLC/MS analysis | 2022 | Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4 | Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models. |
AID1467736 | Cytotoxicity against human HuH7 after 4 to 5 days by Cell-Titer Glo viability assay | 2018 | Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6 | The ProTide Prodrug Technology: From the Concept to the Clinic. |
AID1880206 | Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability measured after 1 to 2 hrs by MTS colorimetric assay | 2022 | ACS medicinal chemistry letters, May-12, Volume: 13, Issue:5 | Discovery of 2-Phenylquinolines with Broad-Spectrum Anti-coronavirus Activity. |
AID1853878 | Antiviral activity against Measles Rec.rMVEZGFP(3) infected in human HeLa cells assessed as reduction in viral replication incubated for 48 to 144 hrs by fluorescence based assay | 2022 | ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3 | Phosphoramidate Prodrugs Continue to Deliver, The Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2. |
AID1898394 | AUC in human plasma at 3 to 225 mg, iv administered as 2 hr infusion | 2022 | Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4 | Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models. |
AID1898393 | Toxicity in BALB/c mouse infected with MHV-A59 assessed as change in body weight at 100 mg/kg, ig administered at 0.5 hrs post infection followed by 50 mg/kg administered daily measured upto 14 days | 2022 | Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4 | Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models. |
AID1764949 | Drug metabolism in cynomolgus monkey assessed as 1-NTP metabolite concentration in trachea at 20 mg/kg, iv measured after 24 hrs by LC-MS/MS analysis | |||
AID1898381 | Tmax in Sprague-Dawley rat at 30 mg/kg, iv measured over 48 hrs by HPLC/MS analysis | 2022 | Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4 | Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models. |
AID1750789 | Antiviral activity against Human coronavirus 229E infected in human embryonic lung fibroblast cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by microscopy | 2021 | Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9 | Betulonic Acid Derivatives Interfering with Human Coronavirus 229E Replication via the nsp15 Endoribonuclease. |
AID1853894 | Antiviral activity against SARS-CoV-2 infected in human Calu-3 cells assessed as reduction in viral replication at MOI of 0.01 measured after 72 hrs by qRT-PCR analysis | 2022 | ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3 | Phosphoramidate Prodrugs Continue to Deliver, The Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2. |
AID1467732 | Antiviral activity against Ebolavirus infected in human HeLa cells after 48 hrs by immuno-staining assay | 2018 | Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6 | The ProTide Prodrug Technology: From the Concept to the Clinic. |
AID1467733 | Antiviral activity against Ebolavirus infected in human HuH7 cells after 3 days by end point dilution assay | 2018 | Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6 | The ProTide Prodrug Technology: From the Concept to the Clinic. |
AID1707635 | Antitrypanosomal activity against Trypanosoma cruzi infected in human MRC-5 SV2 cells | 2021 | European journal of medicinal chemistry, Feb-15, Volume: 212 | Synthesis and evaluation of a collection of purine-like C-nucleosides as antikinetoplastid agents. |
AID1321300 | Antiviral activity against Ebolavirus assessed as reduction in viral replication | 2016 | Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23 | Nucleoside Phosphate and Phosphonate Prodrug Clinical Candidates. |
AID656927 | Antiviral activity against Dengue virus type 2 New Guinea C infected in african green monkey Vero E6 cells assessed as inhibition of virus induced cytopathic effect after 24 hrs by MTS assay | 2012 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8 | Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. |
AID1853884 | Antiviral activity against SARS-CoV-2 infected in human A549 cells expressing hACE2 assessed as reduction in viral replication at MOI of 0.025 incubated for 48 hrs by luciferase based assay | 2022 | ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3 | Phosphoramidate Prodrugs Continue to Deliver, The Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2. |
AID1467734 | Cytotoxicity against human primary macrophages after 4 to 5 days by Cell-Titer Glo viability assay | 2018 | Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6 | The ProTide Prodrug Technology: From the Concept to the Clinic. |
AID656926 | Antiviral activity against Yellow fever virus 17D infected in human HeLa cells assessed as inhibition of virus induced cytopathic effect after 24 hrs by MTS assay | 2012 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8 | Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. |
AID1764940 | Drug metabolism in cynomolgus monkey assessed as 1-NTP metabolite concentration in lung tissue at 20 mg/kg, iv measured after 24 hrs by LC-MS/MS analysis | |||
AID1440656 | Cytotoxicity against human Hep2 cells assessed as reduction in cell viability after 4 to 5 days by Cell-Titer Glo assay | 2017 | Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5 | Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. |
AID1764920 | Drug metabolism in HAE cells assessed as 1-NTP metabolite concentration at 1 uM over 48 hrs by LC-MS/MS analysis | |||
AID1898380 | Terminal elimination half life in Sprague-Dawley rat at 30 mg/kg, ig measured over 48 hrs by HPLC/MS analysis | 2022 | Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4 | Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models. |
AID656938 | Cytotoxicity against human MRC5 cells by MTS assay | 2012 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8 | Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. |
AID656930 | Antiviral activity against Parainfluenza 3 C 243 infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathic effect after 24 hrs by MTS assay | 2012 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8 | Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. |
AID1880208 | Antiviral activity against HCoV-229E infected in HEL 299 cells assessed as reduction in virus-induced cytopathic effect preincubated with compound followed by viral infection and measured after 7 days by MTS cell viability assay | 2022 | ACS medicinal chemistry letters, May-12, Volume: 13, Issue:5 | Discovery of 2-Phenylquinolines with Broad-Spectrum Anti-coronavirus Activity. |
AID1764952 | Drug metabolism in cynomolgus monkey assessed as total metabolite concentration in liver at 20 mg/kg, iv measured after 24 hrs by LC-MS/MS analysis | |||
AID1764915 | Selectivity index, ratio of EC50 for HCV 1b infected in human Huh-7 cells to EC50 for RSV A2 infected in HEp-2 cells | |||
AID1764903 | Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability incubated for 4 to 5 days by CellTiter Glo viability assay | |||
AID1853899 | Antiviral activity against SARS-CoV-2 infected in human PSC-derived lung epithelial cells assessed as reduction in viral replication | 2022 | ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3 | Phosphoramidate Prodrugs Continue to Deliver, The Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2. |
AID1764908 | Permeability across apical to basolateral side in human Caco-2 cells | |||
AID1707634 | Antitrypanosomal activity against Trypanosoma brucei rhodesiense | 2021 | European journal of medicinal chemistry, Feb-15, Volume: 212 | Synthesis and evaluation of a collection of purine-like C-nucleosides as antikinetoplastid agents. |
AID1440654 | Antiviral activity against Respiratory syncytial virus A2 infected in human Hep2 cells assessed as reduction of virus-induced cytopathic effect after 4 days by Cell-Titer Glo assay | 2017 | Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5 | Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. |
AID1880209 | Selectivity index, ratio of CC50 for cytotoxicity against HEL 299 cells to EC50 for antiviral activity against HCoV-229E infected in HEL 299 cells | 2022 | ACS medicinal chemistry letters, May-12, Volume: 13, Issue:5 | Discovery of 2-Phenylquinolines with Broad-Spectrum Anti-coronavirus Activity. |
AID1764937 | Drug metabolism in cynomolgus monkey assessed as 1-NTP metabolite concentration in PBMC at 20 mg/kg, iv measured after 24 hrs by LC-MS/MS analysis | |||
AID656936 | Cytotoxicity against human HeLa cells by MTS assay | 2012 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8 | Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. |
AID656941 | Cmax in human HuH7 cells assessed as triphosphate concentration per million cells at 10 uM incubated for 24 hrs measured after washout by LC-MS analysis | 2012 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8 | Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. |
AID656937 | Cytotoxicity against human HuH7 cells by MTS assay | 2012 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8 | Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. |
AID1898385 | Oral bioavailability in Sprague-Dawley rat at 30 mg/kg measured over 48 hrs by HPLC/MS analysis | 2022 | Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4 | Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models. |
AID1898376 | Cytotoxicity against human Caco-2 cells assessed as reduction in cell viability upto 50 uM measured for 48 hrs by CCK8 assay | 2022 | Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4 | Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models. |
AID1853872 | Antiviral activity against MARV Rec. Bat371-GFP infected in human Huh-7 cells assessed as reduction in viral replication incubated for 48 to 144 hrs by fluorescence based assay | 2022 | ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3 | Phosphoramidate Prodrugs Continue to Deliver, The Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2. |
AID1880205 | Antiviral activity against SARS-CoV-2 infected in eGFP expressing African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect measured after 4 days post infection by laser scanning microscopic analysis | 2022 | ACS medicinal chemistry letters, May-12, Volume: 13, Issue:5 | Discovery of 2-Phenylquinolines with Broad-Spectrum Anti-coronavirus Activity. |
AID1440651 | Lipophilicity, log D of the compound after 30 mins by HPLC/UV method | 2017 | Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5 | Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. |
AID1467731 | Antiviral activity against Ebolavirus infected in human primary macrophages after 48 hrs by immuno-staining assay | 2018 | Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6 | The ProTide Prodrug Technology: From the Concept to the Clinic. |
AID1764934 | AUCinfinity in cynomolgus monkey at 20 mg/kg, iv after 30 mins by LC-MS/MS analysis | |||
AID1880210 | Antiviral activity against HCoV-OC43 infected in HEL 299 cells assessed as reduction in virus-induced cytopathic effect preincubated with compound followed by viral infection and measured after 7 days by MTS cell viability assay | 2022 | ACS medicinal chemistry letters, May-12, Volume: 13, Issue:5 | Discovery of 2-Phenylquinolines with Broad-Spectrum Anti-coronavirus Activity. |
AID1764930 | Clearance in cynomolgus monkey at 20 mg/kg, iv after 30 mins by LC-MS/MS analysis | |||
AID1764904 | Antiviral activity against HCV 1b infected in human Huh-7 cells assessed as reduction in viral replication measured after 3 days by dual-Glo luciferase assay | |||
AID1853886 | Antiviral activity against SARS-CoV-2 infected in HAEC cells assessed as reduction in viral replication incubated for 1.5 hrs followed by virus removal upto 24 hrs and subsequent replacement of medium containing compound by RT-qPCR analysis | 2022 | ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3 | Phosphoramidate Prodrugs Continue to Deliver, The Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2. |
AID1707637 | Cytotoxicity against human MRC-5 SV2 cells assessed as reduction in cell viability | 2021 | European journal of medicinal chemistry, Feb-15, Volume: 212 | Synthesis and evaluation of a collection of purine-like C-nucleosides as antikinetoplastid agents. |
AID656934 | Cytotoxicity against african green monkey Vero cells by MTS assay | 2012 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8 | Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. |
AID1764955 | Drug metabolism in cynomolgus monkey assessed as total metabolite concentration in kidney at 20 mg/kg, iv measured after 24 hrs by LC-MS/MS analysis | |||
AID656925 | Antiviral activity against Hepatitis C virus genotype 1b infected in human HuH7 cells assessed as inhibition of virus induced cytopathic effect after 24 hrs by MTS assay | 2012 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8 | Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. |
AID1707636 | Antileishmanial activity against Leishmania infantum infected in mouse primary macrophages | 2021 | European journal of medicinal chemistry, Feb-15, Volume: 212 | Synthesis and evaluation of a collection of purine-like C-nucleosides as antikinetoplastid agents. |
AID1880204 | Cytotoxicity against HEL 299 cells assessed as reduction in cell viability measured after 1 to 2 hrs by MTS colorimetric assay | 2022 | ACS medicinal chemistry letters, May-12, Volume: 13, Issue:5 | Discovery of 2-Phenylquinolines with Broad-Spectrum Anti-coronavirus Activity. |
AID1764911 | Oral bioavailability in dog | |||
AID1750790 | Cytotoxicity against mock-infected human embryonic lung fibroblast cells incubated for 5 days by MTS assay | 2021 | Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9 | Betulonic Acid Derivatives Interfering with Human Coronavirus 229E Replication via the nsp15 Endoribonuclease. |
AID1898386 | Antiviral activity against SARS-CoV-2 infected in AAV-human ACE2 transduced BALB/c mouse assessed as viral clearance in lungs at 25 mg/kg/day, ip administered 1 day prior to viral infection and measured after 2 days post infection by focus forming assay | 2022 | Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4 | Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models. |
AID1764906 | Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by CellTiter Glo viability assay | |||
AID656939 | Cytotoxicity against dog MDCK cells by MTS assay | 2012 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8 | Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. |
AID1898375 | Cytotoxicity against human Calu-3 cells assessed as reduction in cell viability upto 50 uM measured for 48 hrs by CCK8 assay | 2022 | Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4 | Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models. |
AID1853896 | Antiviral activity against SARS-CoV-2 infected in human Calu-3 2B4 cells assessed as reduction in viral replication at MOI of 0.01 preincubated for 2 hrs followed by viral infection for 30 mins and subsequent virus removal and addition of medium containin | 2022 | ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3 | Phosphoramidate Prodrugs Continue to Deliver, The Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2. |
AID1853892 | Antiviral activity against SARS-CoV-2 infected in human Caco-2 cells assessed as reduction in viral replication at MOI of 0.01 measured after 72 hrs by qRT-PCR analysis | 2022 | ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3 | Phosphoramidate Prodrugs Continue to Deliver, The Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2. |
AID1898377 | AUC(0 to t) in Sprague-Dawley rat at 30 mg/kg, iv measured over 48 hrs by HPLC/MS analysis | 2022 | Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4 | Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models. |
AID1440658 | Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 to 5 days by Cell-Titer Glo assay | 2017 | Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5 | Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. |
AID1467735 | Cytotoxicity against human HeLa after 4 to 5 days by Cell-Titer Glo viability assay | 2018 | Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6 | The ProTide Prodrug Technology: From the Concept to the Clinic. |
AID1880207 | Selectivity index, ratio of CC50 for cytotoxicity against African green monkey Vero E6 cells to EC50 for antiviral activity against SARS-CoV-2 infected in eGFP expressing African green monkey Vero E6 cells | 2022 | ACS medicinal chemistry letters, May-12, Volume: 13, Issue:5 | Discovery of 2-Phenylquinolines with Broad-Spectrum Anti-coronavirus Activity. |
AID1764943 | Drug metabolism in cynomolgus monkey assessed as 1-NTP metabolite concentration in lower bronchi at 20 mg/kg, iv measured after 24 hrs by LC-MS/MS analysis | |||
AID1898374 | Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability upto 50 uM measured for 48 hrs by CCK8 assay | 2022 | Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4 | Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models. |
AID1898371 | Antiviral activity against SARS-COV 2 infected in human Calu-3 cells assessed as inhibition of viral replication after 48 hrs by qRT-PCR analysis | 2022 | Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4 | Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models. |
AID1764918 | Drug metabolism in human HEp-2 cells assessed as 1-NTP metabolite concentration at 1 uM over 48 hrs by LC-MS/MS analysis | |||
AID1898383 | Cmax in Sprague-Dawley rat at 30 mg/kg, iv measured over 48 hrs by HPLC/MS analysis | 2022 | Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4 | Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models. |
AID1898390 | Antiviral activity against MHV-A59 infected in BALB/c mouse assessed as improvement in survival at 100 mg/kg, ip administered at 0.5 hrs post infection followed by 50 mg/kg administered daily measured upto 14 days | 2022 | Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4 | Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models. |
AID1898372 | Antiviral activity against SARS-COV 2 infected in African green monkey Vero E6 cells assessed as inhibition of viral replication after 48 hrs by qRT-PCR analysis | 2022 | Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4 | Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models. |
AID1750809 | Inhibition of nsp15 K60R drug-resistant mutant in Human coronavirus 229E infected in human embryonic lung fibroblast cells assessed as reduction in virus yield | 2021 | Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9 | Betulonic Acid Derivatives Interfering with Human Coronavirus 229E Replication via the nsp15 Endoribonuclease. |
AID1853870 | Antiviral activity against Ebola infected in human HeLa cells assessed as reduction in viral replication | 2022 | ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3 | Phosphoramidate Prodrugs Continue to Deliver, The Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2. |
AID656932 | Antiviral activity against Coxsackievirus A7 infected in human MRC5 cells assessed as inhibition of virus induced cytopathic effect after 24 hrs by MTS assay | 2012 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8 | Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. |
AID1764910 | Oral bioavailability in Sprague-Dawley rat at 8 mg/kg by LC-MS/MS method | |||
AID1440657 | Cytotoxicity against human HuH7 cells assessed as reduction in cell viability after 3 days by calcein-AM dye based fluorescence assay | 2017 | Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5 | Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. |
AID1853880 | Antiviral activity against Measles virus infected in HMVEC cells assessed as reduction in viral replication | 2022 | ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3 | Phosphoramidate Prodrugs Continue to Deliver, The Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2. |
AID1764922 | Drug metabolism in NHBE cells assessed as 1-NTP metabolite concentration at EC50 over 48 hrs by LC-MS/MS analysis | |||
AID1764913 | Selectivity index, ratio of CC50 for human HEp-2 cells to EC50 for RSV A2 infected in HEp-2 cells | |||
AID1764907 | Lipophilicity, log D of compound in acetonitrile and water shaken for 30 mins by HPLC/UV analysis | |||
AID1898389 | Antiviral activity against MHV-A59 infected in BALB/c mouse assessed as improvement in survival at 100 mg/kg, ig administered at 0.5 hrs post infection followed by 50 mg/kg administered daily measured upto 14 days | 2022 | Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4 | Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models. |
AID656935 | Cytotoxicity against african green monkey Vero E6 cells by MTS assay | 2012 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8 | Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. |
AID1764914 | Antiviral activity against RSV infected in NHBE cells after 3 days by ONE-Glo luciferase assay | |||
AID1898387 | Toxicity AAV-human ACE2 transduced BALB/c mouse infected with SARS-COV2 assessed as loss of body weight at 25 mg/kg/day, ip administered 1 day prior to viral infection and treated for 8 days | 2022 | Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4 | Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models. |
AID1898392 | Antiviral activity against MHV-A59 infected in BALB/c mouse assessed as reduction in viral titer in liver at 100 mg/kg, ip administered at 0.5 hrs post infection followed by 50 mg/kg administered daily measured upto 14 days by qRT-PCR analysis | 2022 | Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4 | Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models. |
AID1764933 | Cmax in cynomolgus monkey at 20 mg/kg, iv after 30 mins by LC-MS/MS analysis | |||
AID1764902 | Antiviral activity against RSV A2 infected in HEp-2 cells assessed as reduction in virus-induced cytopathic effect after 4 days by CellTiter Glo viability assay | |||
AID1764921 | Drug metabolism in human HEp-2 cells assessed as 1-NTP metabolite concentration at EC50 over 48 hrs by LC-MS/MS analysis | |||
AID1764931 | Volume of distribution at steady state in cynomolgus monkey at 20 mg/kg, iv after 30 mins by LC-MS/MS analysis | |||
AID1853876 | Antiviral activity against Nipah B2004 infected in human NCI-H358 cells assessed as reduction in viral replication incubated for 48 to 144 hrs by reporter virus assay | 2022 | ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3 | Phosphoramidate Prodrugs Continue to Deliver, The Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2. |
AID1898391 | Antiviral activity against MHV-A59 infected in BALB/c mouse assessed as reduction in viral titer in liver at 100 mg/kg, ig administered at 0.5 hrs post infection followed by 50 mg/kg administered daily measured upto 14 days by qRT-PCR analysis | 2022 | Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4 | Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models. |
AID1853890 | Antiviral activity against SARS-CoV-2 infected in African green monkey Vero E6 cells assessed as reduction in viral replication | 2022 | ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3 | Phosphoramidate Prodrugs Continue to Deliver, The Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2. |
AID1898384 | Cmax in Sprague-Dawley rat at 30 mg/kg, ig measured over 48 hrs by HPLC/MS analysis | 2022 | Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4 | Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models. |
AID1880211 | Selectivity index, ratio of CC50 for cytotoxicity against HEL 299 cells to EC50 for antiviral activity against HCoV-OC43 infected in HEL 299 cells | 2022 | ACS medicinal chemistry letters, May-12, Volume: 13, Issue:5 | Discovery of 2-Phenylquinolines with Broad-Spectrum Anti-coronavirus Activity. |
AID1764905 | Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability measured after 3 days by dual-Glo luciferase assay | |||
AID656933 | Antiviral activity against Coxsackievirus A21 infected in human MRC5 cells assessed as inhibition of virus induced cytopathic effect after 24 hrs by MTS assay | 2012 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8 | Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. |
AID656929 | Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus induced cytopathic effect after 24 hrs by MTS assay | 2012 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8 | Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. |
AID1440673 | Antiviral activity against Ebolavirus Kikwit infected in human macrophages preincubated with cells for 2 hrs followed by viral infection measured after 48 hrs | 2017 | Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5 | Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. |
AID1778630 | Antiviral activity against SARS-CoV-2 infected in African green monkey Vero E6 cells assessed as rescue of virus reduced eGFP signals by SARS-CoV-2 antiviral assay | 2021 | European journal of medicinal chemistry, Oct-05, Volume: 221 | 1,2,4-Triazolo[1,5-a]pyrimidines: Efficient one-step synthesis and functionalization as influenza polymerase PA-PB1 interaction disruptors. |
AID1853888 | Antiviral activity against SARS-CoV-2 infected in human Huh-7 cells assessed as reduction in virus-induced cytopathic effect at MOI of 0.0037 measured after 4 days by MTS assay | 2022 | ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3 | Phosphoramidate Prodrugs Continue to Deliver, The Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (6.45) | 24.3611 |
2020's | 58 (93.55) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (67.12) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (1.56%) | 5.53% |
Reviews | 7 (10.94%) | 6.00% |
Case Studies | 1 (1.56%) | 4.05% |
Observational | 2 (3.13%) | 0.25% |
Other | 53 (82.81%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |